Oncotelic Issues Year End Message to Shareholders
28. Dezember 2022 08:00 ET
|
Oncotelic Therapeutics, Inc.
– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023- OT-101 commercialization effort expanding on multiple fronts - Manufacturing...